Stan Smith has bought MAIA on 13 days since Aug 2022

Stan V. Smith, Ph.D. is an independent director at MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, including its lead program THIO for non-small cell lung cancer (NSCLC).(

Dr. Smith serves as president of Smith Economics Group, Ltd. in Chicago, providing nationwide economic and financial consulting, with a specialization in litigation economics.( Trained at the University of Chicago, he co-authored the first textbook on economic damages and has taught as an adjunct professor at the University of Chicago and DePaul University College of Law, where he created the first U.S. course in forensic economics.( An original investor since MAIA's inception in 2018, Dr. Smith has participated in nearly every private placement financing round and recently purchased shares, including 100,000 shares in November 2024, 15,000 shares on November 26, 2025, and additional acquisitions in December 2025, holding over 1.3 million shares beneficially through The Stan V. Smith Trust Dated 1993.(

Written by Perplexity from public sources.